Your browser doesn't support javascript.
A 1-Pot Synthesis of the SARS-CoV-2 Mpro Inhibitor Nirmatrelvir, the Key Ingredient in Paxlovid.
Caravez, Juan C; Iyer, Karthik S; Kavthe, Rahul D; Kincaid, Joseph R A; Lipshutz, Bruce H.
  • Caravez JC; Department of Chemistry & Biochemistry, University of California, Santa Barbara, Santa Barbara, California 93106, United States.
  • Iyer KS; Department of Chemistry & Biochemistry, University of California, Santa Barbara, Santa Barbara, California 93106, United States.
  • Kavthe RD; Department of Chemistry & Biochemistry, University of California, Santa Barbara, Santa Barbara, California 93106, United States.
  • Kincaid JRA; Department of Chemistry & Biochemistry, University of California, Santa Barbara, Santa Barbara, California 93106, United States.
  • Lipshutz BH; Department of Chemistry & Biochemistry, University of California, Santa Barbara, Santa Barbara, California 93106, United States.
Org Lett ; 24(49): 9049-9053, 2022 12 16.
Article in English | MEDLINE | ID: covidwho-2150978
ABSTRACT
A newly devised route to the Pfizer drug nirmatrelvir is reported that reduces the overall sequence to a 1-pot process and relies on a commercially available, green coupling reagent, T3P. The overall yield of the targeted material, isolated as its MTBE solvate, is 64%.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Limits: Humans Language: English Journal: Org Lett Journal subject: Biochemistry Year: 2022 Document Type: Article Affiliation country: Acs.orglett.2c03683

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Limits: Humans Language: English Journal: Org Lett Journal subject: Biochemistry Year: 2022 Document Type: Article Affiliation country: Acs.orglett.2c03683